Elucidation of mutant p53-medidated mechanisms in promoting metastatic esophageal cancer
阐明突变型 p53 介导的促进转移性食管癌的机制
基本信息
- 批准号:10537915
- 负责人:
- 金额:$ 4.59万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-09-01 至 2025-08-31
- 项目状态:未结题
- 来源:
- 关键词:3-DimensionalATAC-seqAdvisory CommitteesAffectAutocrine CommunicationAwardBindingBromodomainCancer EtiologyCell LineCellsChromatinClinicalColony-Stimulating Factor ReceptorsCommunicationDNA BindingDNA Binding DomainDataDevelopment PlansDiagnosisDiseaseEpigenetic ProcessEsophageal Squamous Cell CarcinomaEsophageal carcinomaEventFacultyFoundationsFutureGeneticGenetic TranscriptionGenomicsGoalsGrantHomologous GeneHumanIn VitroLongitudinal StudiesM cellMacrophage Colony-Stimulating FactorMalignant Epithelial CellMalignant NeoplasmsMalignant neoplasm of esophagusManuscriptsMediatingMediator of activation proteinMedical centerMentorshipMetastatic Neoplasm to the LungMetastatic toMissense MutationModelingMolecular ConformationMusMutateMutationNeoplasm MetastasisOncogenicOrganoidsOutcomePathway interactionsPatientsPharmacologyPositioning AttributePre-Clinical ModelPrimary NeoplasmPrognosisPropertyReaderRecurrenceRegulationResourcesRoleScientistSignal PathwaySignal TransductionSquamous cell carcinomaSurvival RateTP53 geneTestingTherapeuticThinkingTrainingTumor Cell InvasionTumor PromotionTumor Suppressor ProteinsTumor-associated macrophagesUniversitiesUp-RegulationWorkWritinganticancer researchbasebase editingcancer typecareercareer developmentcollaborative environmenteffective therapygain of functionimprovedin vivoin vivo Modelmacrophagemetastatic esophagealmigrationmortalitymouse modelmutantneoplastic cellnew therapeutic targetnovel therapeutic interventionprogramsskillssmall hairpin RNAsmall moleculetenure tracktranscriptome sequencingtranscriptomicstumortumor growthtumorigenesistumorigenic
项目摘要
PROJECT SUMMARY
Esophageal Squamous Cell Carcinoma (ESCC), the predominant subtype of esophageal cancer worldwide is
one of the most known lethal cancers. The prognosis of metastatic ESCC is dismal with a 5-year relative survival
rate of only 5%. Mutations in TP53 (mouse homolog Trp53), which are detected in approximately 70% of ESCC
patients, contribute to tumor metastasis and poor prognosis. To understand the mechanisms of Trp53R172H-
mediated metastasis, which is one of the “hotspot” mutations in ESCC, we utilized mouse models and performed
RNA-Seq on metastatic ESCC cells generated from this model, from which I identified Colony stimulating factor-
1 (Csf-1) to be significantly upregulated. While it is canonically involved in polarization of tumor-associated
macrophages through binding to its receptor CSF-1R, my data demonstrate the existence of autocrine signaling
that is potentially co-regulated by epigenetic reader Bromodomain-Containing Domain 4 (BRD4). The
overarching hypothesis of this study is that CSF-1/CSF-1R autocrine signaling is one of the major mechanisms
by which missense TP53 mutations can promote invasion and lung metastasis in ESCC. I will test this hypothesis
through the following interrelated Specific Aims: (1) Elucidate the role of Trp53R172H-mediated CSF-1/CSF-1R
signaling pathway in promoting invasion and lung metastasis in ESCC, (2) Investigate BRD4 as a candidate co-
regulator of Trp53R172H that contributes to CSF-1 upregulation and assess the anti-tumorigenic efficacy of
inhibiting BRD4, and (3) Delineate the tumorigenic, as well as epigenetic/transcriptomic states mediated by
missense p53 mutations recurrent in ESCC patients and impact upon CSF-1/CSF-1R signaling. To accomplish
Aim 1, I will assess the role of CSF-1/CSF-1R signaling in proliferation, migration, primary tumor and 3D organoid
formation, invasion and lung metastasis, as well as its downstream effectors through utilizing in vitro and
complementary in vivo approaches. I will accomplish Aim 2 by studying the direct interaction of p53-R172H and
BRD4, and also their shared DNA binding motifs through CUT&RUN-Seq. Additionally, I will genetically delete
and pharmacologically inhibit BRD4 to evaluate their effects on tumorigenesis and lung metastasis. To
accomplish Aim 3, I will introduce p53 mutations through base editing and evaluate their distinct roles in pro-
oncogenic activities. I will also investigate how these mutations affect the transcriptional expression of factors in
CSF-1/CSF-1R signaling pathway during metastasis, and also conduct single-cell ATAC-Seq on mouse primary
and metastatic tumors to evaluate their chromatin accessibility. This study will elucidate the tumor cell intrinsic
mechanisms underlying ESCC metastasis, which will ultimately open new avenues in developing therapeutic
strategies for metastatic ESCC patients that can be extended to other SCCs. I will develop skills in analytical
thinking, technical approaches, scientific communication, grant and manuscript writing, and mentorship with the
support and resources available through my sponsors, advisory committee and graduate program, which will be
critical to accomplish my long-standing career goal to become a tenure-track faculty to conduct cancer research.
项目概要
食管鳞状细胞癌 (ESCC) 是全球食管癌的主要亚型
最知名的致命癌症之一。转移性食管鳞癌的预后很差,相对生存期为 5 年
率仅为5%。 TP53(小鼠同源物 Trp53)突变,在大约 70% 的 ESCC 中检测到
患者,导致肿瘤转移,预后不良。了解 Trp53R172H- 的机制
介导的转移,这是食管鳞癌的“热点”突变之一,我们利用小鼠模型并进行了
对从该模型生成的转移性 ESCC 细胞进行 RNA 测序,我从中识别出了集落刺激因子 -
1 (Csf-1) 显着上调。虽然它典型地参与肿瘤相关的极化
巨噬细胞通过与其受体CSF-1R结合,我的数据证明了自分泌信号的存在
它可能受到表观遗传阅读器含溴结构域 4 (BRD4) 的共同调节。这
本研究的总体假设是 CSF-1/CSF-1R 自分泌信号传导是主要机制之一
TP53错义突变可促进食管鳞癌的侵袭和肺转移。我将测试这个假设
通过以下相互关联的具体目标:(1)阐明Trp53R172H介导的CSF-1/CSF-1R的作用
信号通路促进 ESCC 侵袭和肺转移,(2)研究 BRD4 作为候选协同蛋白
Trp53R172H 的调节因子有助于 CSF-1 上调并评估其抗肿瘤功效
抑制 BRD4,以及 (3) 描述致瘤性以及表观遗传/转录组状态
ESCC 患者中反复出现的错义 p53 突变及其对 CSF-1/CSF-1R 信号传导的影响。为了完成
目标 1,我将评估 CSF-1/CSF-1R 信号传导在增殖、迁移、原发肿瘤和 3D 类器官中的作用
通过体外和实验研究其形成、侵袭和肺转移及其下游效应子
互补的体内方法。我将通过研究 p53-R172H 和 p53-R172H 的直接相互作用来实现目标 2
BRD4,以及它们通过 CUT&RUN-Seq 共享的 DNA 结合基序。另外,我会基因删除
并通过药理抑制BRD4来评估其对肿瘤发生和肺转移的影响。到
为了实现目标 3,我将通过碱基编辑引入 p53 突变,并评估它们在 pro-
致癌活动。我还将研究这些突变如何影响因子的转录表达
转移过程中的CSF-1/CSF-1R信号通路,并对小鼠原代细胞进行单细胞ATAC-Seq
和转移性肿瘤,以评估其染色质可及性。这项研究将阐明肿瘤细胞内在的
ESCC 转移的机制,最终将为开发治疗方法开辟新途径
针对转移性食管鳞癌患者的策略可以扩展到其他鳞状细胞癌。我将培养分析技能
思维、技术方法、科学交流、资助和手稿写作以及与
通过我的赞助商、咨询委员会和研究生项目提供的支持和资源,这将是
这对于实现我长期的职业目标至关重要,即成为一名进行癌症研究的终身教授。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Gizem Efe其他文献
Gizem Efe的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Gizem Efe', 18)}}的其他基金
Elucidation of mutant p53-medidated mechanisms in promoting metastatic esophageal cancer
阐明突变型 p53 介导的促进转移性食管癌的机制
- 批准号:
10689716 - 财政年份:2022
- 资助金额:
$ 4.59万 - 项目类别:
相似国自然基金
基于ATAC-seq与DNA甲基化测序探究染色质可及性对莲两生态型地下茎适应性分化的作用机制
- 批准号:
- 批准年份:2024
- 资助金额:0.0 万元
- 项目类别:省市级项目
利用ATAC-seq联合RNA-seq分析TOP2A介导的HCC肿瘤细胞迁移侵
袭的机制研究
- 批准号:
- 批准年份:2024
- 资助金额:0.0 万元
- 项目类别:省市级项目
面向图神经网络ATAC-seq模体识别的最小间隔单细胞聚类研究
- 批准号:62302218
- 批准年份:2023
- 资助金额:30.00 万元
- 项目类别:青年科学基金项目
基于ATAC-seq策略挖掘穿心莲基因组中调控穿心莲内酯合成的增强子
- 批准号:
- 批准年份:2022
- 资助金额:33 万元
- 项目类别:地区科学基金项目
基于单细胞ATAC-seq技术的C4光合调控分子机制研究
- 批准号:
- 批准年份:2021
- 资助金额:30 万元
- 项目类别:青年科学基金项目
基于ATAC-seq技术研究交叉反应物质197调控TFEB介导的自噬抑制子宫内膜异位症侵袭的分子机制
- 批准号:82001520
- 批准年份:2020
- 资助金额:24.0 万元
- 项目类别:青年科学基金项目
靶向治疗动态调控肺癌细胞DNA可接近性的ATAC-seq分析
- 批准号:81802809
- 批准年份:2018
- 资助金额:21.0 万元
- 项目类别:青年科学基金项目
运用ATAC-seq技术分析染色质可接近性对犏牛初级精母细胞基因表达的调控作用
- 批准号:31802046
- 批准年份:2018
- 资助金额:27.0 万元
- 项目类别:青年科学基金项目
基于ATAC-seq和RNA-seq研究CWIN调控采后番茄果实耐冷性作用机制
- 批准号:31801915
- 批准年份:2018
- 资助金额:24.0 万元
- 项目类别:青年科学基金项目
基于ATAC-seq高精度预测染色质相互作用的新方法和基于增强现实的3D基因组数据可视化
- 批准号:31871331
- 批准年份:2018
- 资助金额:59.0 万元
- 项目类别:面上项目
相似海外基金
Project #2 Integrated single-nucleus multi-omics (ATAC-seq+RNA-seq or chromatin accessibility + RNA-seq) of human TGs
项目
- 批准号:
10806548 - 财政年份:2023
- 资助金额:
$ 4.59万 - 项目类别:
A transposase system for integrative ChIP-exo and ATAC-seq analysis at single-cell resolution
用于单细胞分辨率综合 ChIP-exo 和 ATAC-seq 分析的转座酶系统
- 批准号:
10210424 - 财政年份:2018
- 资助金额:
$ 4.59万 - 项目类别:
EAPSI: Developing Single Nucleus ATAC-seq to Map the Ageing Epigenome
EAPSI:开发单核 ATAC-seq 来绘制衰老表观基因组图谱
- 批准号:
1714070 - 财政年份:2017
- 资助金额:
$ 4.59万 - 项目类别:
Fellowship Award
A cloud-based learning module to analyze ATAC-seq and single cell ATAC-seq data
基于云的学习模块,用于分析 ATAC-seq 和单细胞 ATAC-seq 数据
- 批准号:
10558379 - 财政年份:2001
- 资助金额:
$ 4.59万 - 项目类别: